Drug studies in humans
Last updated: 2025 Mar 18
Total hit(s): 7860
S.No.
1
39643949
Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia.
Expert Rev Vaccines
2025 Dec
4.37
1
2
40077853
Characterization of the binding features between SARS-CoV-2 5'-proximal transcripts of genomic RNA and nucleocapsid proteins.
RNA Biol
2025 Dec
1
3
39834144
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants.
Expert Rev Vaccines
2025 Dec
4.37
1
4
40028815
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models.
Hum Vaccin Immunother
2025 Dec
4.7
1
5
39865693
Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial.
Hum Vaccin Immunother
2025 Dec
4.7
1
6
39720838
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged >/=18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Expert Rev Vaccines
2025 Dec
4.37
1
7
39887328
Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population.
J Med Econ
2025 Dec
1
8
40051347
Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.
Hum Vaccin Immunother
2025 Dec
4.7
1
9
40045463
The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.
Hum Vaccin Immunother
2025 Dec
4.7
1
10
40046771
Production and cryo-electron microscopy structure of an internally tagged SARS-CoV-2 spike ecto-domain construct.
J Struct Biol X
2025 Jun
1
11
39987705
Decoding SARS-CoV-2 variants: Mutations, viral stability, and breakthroughs in vaccines and therapies.
Biophys Chem
2025 May-Jun
1.75
1
12
39837378
In-vivo implementation of the HPTLC methodology to rat plasma for the concurrent determination of a novel combination therapy for the management of COVID-19 (favipiravir and nitazoxanide).
Anal Biochem
2025 May
1
13
39983537
SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
Vaccine
2025 Apr 2
3.31
1
14
39847906
Hyperplex PCR enables highly multiplexed analysis of point mutations in wastewater: Long-term SARS-CoV-2 variant surveillance in Sweden as a case study.
Water Res
2025 Apr 15
8.14
1
15
40043614
Structure and dynamics of Alpha B.1.1.7 SARS-CoV-2 S-protein in complex with Fab of neutralizing antibody REGN10987.
Biochem Biophys Res Commun
2025 Apr 1
2.73
1
16
39884914
The immunopathogenesis of a cytokine storm: The key mechanisms underlying severe COVID-19.
Cytokine Growth Factor Rev
2025 Apr
5.5
1
17
40025551
Association of TNFRSF13B Gene Polymorphisms With SARS-CoV-2 Infection, Severity, and Humoral Immune Response in a Moroccan Population.
Int J Immunogenet
2025 Apr
1
18
40023068
Exploring the therapeutic potential of HAPC in COVID-19-induced acute lung injury.
Phytomedicine
2025 Apr
7.2
1
19
40057761
Impact of single nucleotide polymorphism of IL-27P28 rs153109 and IFITM3 rs12252 on susceptibility and severity of COVID-19 in Egyptian patients: a case control study.
Virol J
2025 Mar 8
2.45
1
20
40055264
COVID-19 booster doses reduce sex disparities in antibody responses among nursing home residents.
Aging Clin Exp Res
2025 Mar 8
2.37
1
21
40056469
Data Interoperability in COVID-19 Vaccine Trials: Methodological Approach in the VACCELERATE Project.
JMIR Med Inform
2025 Mar 7
2.58
1
22
40058446
Carbon monoxide inhibits human bronchial epithelial CCL5 and IL-6 secretion induced by SARS-CoV-2 spike RBD protein.
Exp Cell Res
2025 Mar 7
3.24
1
23
40056806
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics.
Vaccine
2025 Mar 7
3.31
1
24
40054138
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
Vaccine
2025 Mar 6
3.31
1
25
39973207
Reactive oxygen species-mediated cytotoxic and DNA-damaging mechanism of N(4)-hydroxycytidine, a metabolite of the COVID-19 therapeutic drug molnupiravir.
Free Radic Res
2025 Mar 6
1